Medicare Enrolled

Dr. Padma Chimata, M.D.

Rheumatology · Katy, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
402 PARK GROVE DRIVE, Katy, TX 77450
2815787438
In practice since 2007 (18 years)
NPI: 1922297068 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Chimata from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Chimata? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Chimata

Dr. Padma Chimata is a rheumatology in Katy, TX, with 18 years in practice. Based on federal Medicare data, Dr. Chimata performed 111,571 Medicare services across 1,950 unique beneficiaries.

Between the years covered by Open Payments, Dr. Chimata received a total of $27,357 from 50 pharmaceutical and/or device companies across 822 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Chimata is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 18 years in practice▲ Top 14% volume in TX$ $27,357 industry payments

Medicare Practice Summary

Medicare Utilization ↗
111,571
Medicare services
Top 14% in TX for rheumatology
1,950
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~6,198 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Certolizumab injection (Cimzia)56,000$4$19
Romosozumab injection (Evenity) for osteoporosis13,860$8$32
Golimumab infusion (Simponi Aria)12,800$10$112
Denosumab injection (Prolia/Xgeva)10,980$18$38
Abatacept infusion (Orencia)9,750$34$112
Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg2,232$13$560
Office visit, established patient (30-39 min)1,727$93$273
Steroid injection (triamcinolone)1,560$1$6
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle597$60$250
Infusion, normal saline solution, 250 cc486$0$31
Administration of chemotherapy into vein, 1 hour or less295$106$356
Aspiration and/or injection of fluid large joint using ultrasound guidance241$78$375
Dxa bone density measurement of forearm, finger, hand, or foot238$33$98
Infusion into a vein for hydration, each additional hour237$10$38
Bone density scan (DEXA)204$39$262
New patient office visit, complex (60-74 min)93$161$438
Office visit, established patient, complex (40-54 min)73$144$271
Injection, zoledronic acid, 1 mg70$7$250
Dxa bone density measurement of hip, pelvis, spine including spine fracture assessment43$54$176
Injection into tendon or ligament29$44$231
Ultrasonic guidance for needle placement26$47$512
Drug injection, under skin or into muscle16$11$138
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less14$53$312
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
20.9% high complexity
77.0% medium
2.2% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$27,357
Total received (2018-2024)
Avg $3,908/year across 7 years
Top 15% in TX for rheumatology
50
Companies
822
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$16,318 (59.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$11,039 (40.4%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$8,402
2023
$7,596
2022
$2,637
2021
$1,191
2020
$368
2019
$4,190
2018
$2,972

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$12,476
UCB, Inc.
$2,219
Zimmer Biomet Holdings, Inc.
$1,574
AstraZeneca Pharmaceuticals LP
$1,155
Janssen Biotech, Inc.
$1,053
PFIZER INC.
$861
GlaxoSmithKline, LLC.
$803
Novartis Pharmaceuticals Corporation
$688
AbbVie Inc.
$668
Lilly USA, LLC
$556
ABBVIE INC.
$537
AbbVie, Inc.
$495
Celgene Corporation
$413
GENZYME CORPORATION
$409
ANI Pharmaceuticals, Inc.
$321
Aurinia Pharma U.S., Inc.
$320
Radius Health, Inc.
$311
Genentech USA, Inc.
$280
E.R. Squibb & Sons, L.L.C.
$267
Horizon Therapeutics plc
$246
Mallinckrodt Hospital Products Inc.
$178
Sandoz Inc.
$146
Octapharma USA, Inc.
$144
Horizon Pharma plc
$137
Alexion Pharmaceuticals, Inc.
$136
Johnson & Johnson Health Care Systems Inc.
$129
Novo Nordisk Inc
$115
Gilead Sciences, Inc.
$62
Almatica Pharma LLC
$54
SOBI, INC
$53
Mallinckrodt LLC
$52
Boehringer Ingelheim Pharmaceuticals, Inc.
$51
Mallinckrodt Enterprises LLC
$51
Zyla Life Sciences
$49
TerSera Therapeutics LLC
$47
Bioventus LLC
$38
SANOFI-AVENTIS U.S. LLC
$38
MEDAC PHARMA, INC.
$29
Kyowa Kirin, Inc.
$24
Kiniksa Pharmaceuticals, Ltd.
$21
Organon LLC
$20
Hikma Pharmaceuticals USA
$20
Fidia Pharma USA Inc.
$16
Antares Pharma, Inc.
$15
MEDEXUS PHARMA, INC.
$15
Orthogenrx Inc.
$14
Iroko Pharmaceuticals, LLC
$14
Intercept Pharmaceuticals, Inc.
$14
Purdue Pharma L.P.
$12
Organon Llc
$12
Top 3 companies account for 59.5% of total payments
Associated products mentioned in payments ›
ACTHAR · Actemra · Arcalyst · BENLYSTA · Bimzelx · COSENTYX · CYLTEZO · Cimzia · Crysvita · EVENITY · Enbrel · FORTEO · GELSYN 3 · GenVisc 850 · HADLIMA · HUMIRA · HYMOVIS · HYRIMOZ · Humira · ILARIS · INFLECTRA · KEVZARA · KINERET · KRYSTEXXA · Kineret · LUPKYNIS · LYRICA · Mitigare · OCALIVA · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ORENCIA · Otezla · Otrexup · PANZYGA · PURIFIED CORTROPHIN GEL · Prolia · Quzyttir · RAYOS · REMICADE · RENFLEXIS · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · SPRIX · STELARA · STRENSIQ · SYMPROIC · SYNVISC-ONE · TALTZ · TAVNEOS · TERIPARATIDE · TREMFYA · Tavneos · Tymlos · VIMOVO · VIVLODEX · XELJANZ · ZORVOLEX · Zimmer Biomet Instruments and Implants
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (60%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $25 per 100 Medicare services performed
Looking for a rheumatology in Katy?
Compare rheumatologys in the Katy area by procedure volume, costs, and industry payment transparency.
Browse rheumatologys nearby

Geographic Context

Rheumatologys within 10 mi
69
Per 100K population
1.5
County median income
$73,104
Nearest hospital
OCEANS BEHAVIORAL HOSPITAL OF KATY
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Chimata is a mixed practice specialist, with above-average Medicare volume (top 14% in TX), and high industry engagement (low-engagement, top 15%), with 18 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Chimata experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Chimata performed 56,000 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Chimata receive payments from pharmaceutical companies?
Yes. Dr. Chimata received a total of $27,357 from 50 companies across 822 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Chimata's costs compare to other rheumatologys in Katy?
Dr. Chimata's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Chimata) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →